专利号:US-5840915-A 优先权日:1990-01-22 标题:Process for the enatioselective synthesis of intermediates used 发明人:LEE THOMAS BING KIN; WONG GEORGE SEUNG-KIT 权利人:HOECHST MARION ROUSSEL INC 摘要:A process for the stereoselective synthesis of [R]- and [S]-2,3-dihydro-1,3-dimethyl-2-oxo-1H-indole-3-acetonitriles comprises reacting racemic and 5-alkoxy-substituted (+/-)-1,3-dimethyloxindoles with a halogenated acetonitrile in the presence of a substituted N-benzyl cinchoninium, quinidinium, cinchonidinium, or quininium catalyst. The resulting alkylated oxindoles can be converted to primary amines by catalytic reduction in the presence of hydrogen gas. One of the primary amines, such as enantiomers of 3-(2-aminoethyl)-1,3-dihydro-1,3-dimethyl-5-methoxy-2H-indol-2-one, can be enriched by contact with a chiral tartaric acid in an amount sufficient to preferentially precipitate a salt of the chiral acid and one of the enantiomers. The product can be used in the synthesis of stereospecific forms of physostigmine and related compounds having pharmaceutical activity.
专利号:US-5274117-A 优先权日:1990-01-22 标 题:Process for the enantioselective synthesis of intermediates used in the preparation of physostigmine 发明人:LEE THOMAS BING KIN DR; WONG GEORGE S K 权利人:HOECHST ROUSSEL PHARMA 摘要:A process for the stereoselective synthesis of [R]- and [S]-2,3-dihydro-1,3-dimethyl-2-oxo-1H-indole-3-acetonitriles comprises reacting racemic and 5-alkoxy-substituted (+/-)-1,3-dimethyloxindoles with a halogenated acetonitrile in the presence of a substituted N-benzyl cinchoninium, quinidinium, cinchonidinium, or quininium catalyst. The resulting alkylated oxindoles can be converted to primary amines by catalytic reduction in the presence of hydrogen gas. One of the primary amines, such as enantiomers of 3-(2-aminoethyl)-1,3-dihydro-1,3-dimethyl-5-methoxy-2H-indol-2-one, can be enriched by contact with a chiral tartaric acid in an amount sufficient to preferentially precipitate a salt of the chiral acid and one of the enantiomers. The product can be used in the synthesis of stereospecific forms of physostigmine and related compounds having pharmaceutical activity.
专利号:EP-0438796-B1 优先权日:1990-01-22 标题:Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine 发明人:LEE THOMAS BING KIN DR; WONG GEORGE S K 权利人:HOECHST MARION ROUSSEL INC 摘要:A process for the stereoselective synthesis of [R]- and [S]-2,3-dihydro-1,3-dimethyl-2-oxo-1H-indole-3-acetonitriles comprises reacting racemic and 5-alkoxy-substituted (+/-)-1,3-dimethyloxindoles with a halogenated acetonitrile in the presence of a substituted N-benzyl cinchoninium, quinidinium, cinchonidinium, or quininium catalyst. The resulting alkylated oxindoles can be converted to primary amines by catalytic reduction in the presence of hydrogen gas. One of the primary amines, such as enantiomers of 3-(2-aminoethyl)-1,3-dihydro-1,3-dimethyl-5-methoxy-2H-indol-2-one, can be enriched by contact with a chiral tartaric acid in an amount sufficient to preferentially precipitate a salt of the chiral acid and one of the enantiomers. The product can be used in the synthesis of stereospecific forms of physostigmine and related compounds having pharmaceutical activity.
专利号:US-2013165350-A1 优先权日:2011-12-22 标 题:Surface linkers for array synthesis 发明人:KUIMELIS ROBERT; MCGALL GLENN; PAO DEXTER; CHEN ZIHUI; AXELROD TREVOR 权利人:KUIMELIS ROBERT; MCGALL GLENN; PAO DEXTER; CHEN ZIHUI; AXELROD TREVOR; AFFYMETRIX INC 摘要:The present invention provide several methods of derivatizing a surface of a support with one or more linkers thus providing a suitable platform for synthesis of a polymer array, particular a nucleic acid array. Some methods derivatize a surface with a self-assembled monolayer (SAM) of a linker. The SAM confers advantages of hydrolytic stability, broad compatibility with synthesis and detection chemistries, and reduced emergence of latent functional groups during polymer array synthesis. Substrates can also be derivatized with multi-layers of SAMs providing greater hydrolytic stability. Substrates can also be derivatized by synthesizing a linker in situ on the substrate by atom transfer radical polymerization of functional and functional monomers. Appropriate selection of monomers reduces emergence of latent functional groups in subsequent array synthesis.
专利号:US-9512250-B2 优先权日:2012-02-23 标 题 :Manganese catalyzed photopolymerization of fluorinated monomers 发明人:ASANDEI ALEXANDRU D 权利人:UNIV CONNECTICUT 摘要:The disclosure discloses initiating systems for the radical polymerization of alkenes, and especially fluorine substituted alkenes. The polymerization is catalyzed by a metal carbonyl, preferably manganese carbonyl. The polymerization is initiated directly from alkyl halides at room temperature under visible white light. The polymers also allow the synthesis of block copolymers. The process comprises polymerizing at least one alkene monomer in the presence of a halide radical initiator, carbonyl catalyst and a solvent, under reaction conditions and for a time sufficient to polymerize the at least one alkene monomer to form a polymer. The present disclosure provides a method for living polymerization of alkene monomers which provides a high level of macromolecular control over the polymerization process and which leads to uniform and controllable polymeric products. This disclosure also provides a method for activating any halide (Cl, Br, I) chain ends of such polymers for the synthesis of block copolymerizations.
专利号:US-11512097-B2 优先权日:2019-11-25 标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use 发明人:ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO 权利人:AMGEN INC 摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.